EARLY DISEASE CLEARANCE WITH ETRASIMOD AND CORRELATION WITH WEEK 52 OUTCOMES AND BIOMARKERS: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC TRIALS

Fernando Magro  1     Laurent Peyrin-Biroulet  2, 3     Bruce E. Sands  4     Silvio Danese  5     Vipul Jairath  6     Martina Goestch  7     Abhishek Bhattacharjee  8     Joseph Wu  9     Diogo Branquinho  10     Irene Modesto  11    
1 University of Porto and Centro Hospitalar São João, Porto, Portugal
2 University of Lorraine, CHRU-Nancy, Nancy, France
3 University of Lorraine, Inserm, NGERE, Nancy, France
4 Icahn School of Medicine at Mount Sinai, New York, United States
5 IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy
6 Western University, London, Canada
7 Pfizer AG, Zürich, Switzerland
8 Pfizer Healthcare India Pvt. Ltd, Chennai, India
9 Pfizer Inc, Groton, United States
10 Pfizer Inc, New York, United States
11 Pfizer Inc, Madrid, Spain

Topic
IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing